Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
185
resultados
Última actualización
10/03/2026 [07:26:00]
Resultados 175 a 185 de 185
Resumen de: WO2025176879A1
The present invention relates to methods of immunoassay for detecting or monitoring inflammatory bowel disease or a severity thereof in a patient. In certain embodiments, the inflammatory bowel disease may be ulcerative colitis.
Resumen de: WO2025179106A1
A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.
Resumen de: WO2025177282A1
A system for predicting a response to nutritional therapy for treating Crohn's Disease (CD), including a computer with a processor and memory, a machine learning module, wherein the machine learning module is programed to train a model by accepting a training data set comprising multiomics data of subjects with Crohn's disease that were treated by exclusive enteral nutrition (EEN) and a determination if each subject was a responder that successfully responded to the treatment or was a non-responder that unsuccessfully responded to the treatment, and wherein the machine learning module uses the trained model to accept multiomics data of a patient and predict if the patient is a responder or a non-responder.
Resumen de: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Resumen de: EP4607197A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
Resumen de: EP4606910A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Resumen de: JP2025124594A
To provide novel therapies for treating or ameliorating inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, as well as for treating other autoimmune conditions.SOLUTION: The present invention relates to antibodies that specifically bind to one or both of IL27RA and gp130. The present invention further relates to bispecific antibodies that specifically bind to IL27RA and gp130. The present invention also relates to related molecules, e.g., nucleic acids encoding such antibodies or bispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and bispecific antibodies, and their use in diagnostic and therapeutic agents.SELECTED DRAWING: Figure 1
Resumen de: CN120536298A
The invention belongs to the technical field of microorganisms, and discloses lactobacillus fermentum (L.f) LFSJ001 and application of the lactobacillus fermentum (L.f) LFSJ001 in preparation of a product for preventing or treating ulcerative colitis. The lactobacillus fermentum LFSJ001 is subjected to autonomous separation and identification. According to the application disclosed by the invention, a mouse colitis model is constructed by using DSS, and it is found that combined treatment of lactobacillus fermentum LFSJ001 and mesalazine (5-ASA) can enhance improvement of 5-ASA on colitis symptoms, including a plurality of indexes such as a disease activity index, a colon injury index and a spleen index. Therefore, the lactobacillus fermentum LFSJ001 can be used as a combined medicine of the 5-ASA, the medicine effect of the 5-ASA is enhanced, the occurrence and development of the ulcerative colitis are inhibited, the intestinal barrier is improved, and a new diagnosis and treatment direction and strategy are provided for prevention and treatment of the ulcerative colitis.
Resumen de: CN120536347A
The invention discloses a preparation method of an intestinal organ inflammation model based on inflammatory factors, and belongs to the technical field of biomedicine. The invention provides an innovative in-vitro culture method based on intestinal organs, and aims to simulate inflammatory response in inflammatory bowel disease (IBD) and influence of the inflammatory response on intestinal epithelium and stem cells. Specific inflammatory factors IL-22, IFN-gamma and TNF-alpha are introduced into an organoid culture system, an inflammatory environment related to IBD is successfully induced, and a key feature of IBD is observed: expression of a fetal-like intestine stem cell marker gene Sca-1 is remarkably increased. The model fully simulates the repair mechanism of the intestinal tract in inflammatory response. The invention discloses key effects of different inflammatory factors on intestinal epithelium functions and fetal-like intestine stem cells in a repair process, and provides a unique in-vitro platform for deeply researching a repair mechanism. The invention provides a novel in-vitro experimental platform for mechanism research, diagnosis, personalized treatment and drug screening of the inflammatory bowel disease.
Nº publicación: CN120519578A 22/08/2025
Solicitante:
GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU DIGESTIVE DISEASE CENTER THE FIRST PEOPLES HOSPITAL AFFIL
\u5E7F\u5DDE\u5E02\u7B2C\u4E00\u4EBA\u6C11\u533B\u9662\uFF08\u5E7F\u5DDE\u6D88\u5316\u75BE\u75C5\u4E2D\u5FC3\u3001\u5E7F\u5DDE\u533B\u79D1\u5927\u5B66\u9644\u5C5E\u5E02\u4E00\u4EBA\u6C11\u533B\u9662\u3001\u534E\u5357\u7406\u5DE5\u5927\u5B66\u9644\u5C5E\u7B2C\u4E8C\u533B\u9662\uFF09
Resumen de: CN120519578A
The invention provides an application of APOL1 in diagnosis of neonatal necrotizing enterocolitis. Research finds that compared with a control child patient, the APOL1 gene and protein expression level in NEC child patients are remarkably improved for the first time, ROC curve analysis results show that when APOL1 is used for NEC diagnosis, AUC is 0.86, and diagnosis accuracy is high. Therefore, the APOL1 can be used as a specific diagnostic marker of the NEC for assisting clinical diagnosis of the NEC. Furthermore, when the APOL1 is combined with C reactive protein, lymphocyte count (LYM) or hemoglobin level to be used for NEC diagnosis, AUC can be further improved to 0.91-0.94, and the diagnosis accuracy is further improved. The invention provides a novel specific biomarker for diagnosis of NEC, and has important clinical value for early diagnosis and early treatment of NEC.
BOPI
Sede Electrónica
